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Over the last couple of years a number of drugs produced by the pharmaceutical 
sector in Ireland  have fallen out of patent. This change in patent status has had a 
big effect on the value of gross output in the sector and, because of the 
importance of the sector, these changes have impacted on key economic 
aggregates. The purpose of this note is to explain how these changes impact on 
the national accounts.  
 
To simplify the exposition we first concentrate on the effects of the loss of patent 
on the profits of the pharmaceutical sector and how this loss is treated in the 
national accounts. In our conclusions we briefly consider how the loss of patent 
may result in a loss of employment and related real value added in Ireland. 1 
 
The fastest growing sector in Irish manufacturing in recent decades has been 
pharmaceuticals. Many of the top firms in the industry have located plants in 
Ireland, providing a significant share of world output of particular drugs from 
these plants. These pharmaceutical firms have been attracted to Ireland for a 
number of reasons: the low corporation tax rate; the availability of specialist 
skilled labour; serviced sites and a suitable regulatory regime. Many of the drugs 
being produced in the Irish plants have been developed relatively recently and 
are covered by patents. The duration of the patents ensures that the firms can, 
over time, recover the huge cost of developing modern pharmaceuticals.  
 
The patents are for limited periods and, once they run out, it is open to other 
firms anywhere in the world to produce generic equivalents of the drugs 
previously covered by patent2. Even without the entry of generic equivalents into 
the market, the ending of patent cover means that the firm’s profits from 
                                                          
1  Because the wage bill is under 5 per cent of the turnover in the sector, big changes in the turnover of the sector, and 
hence in profits of the sector, can have a much bigger effect on national accounts aggregates than changes in the 
wage bill.  
2  The patents may run out at different dates in different jurisdictions. This may mean that the effects of the ending of a 
patent are spread over a number of quarters, or even years. 
  
producing and selling the drugs are likely to fall. In particular, the owners of the 
original patent may drop the price of the pharmaceuticals to discourage market 
entry by suppliers of generic equivalents. If the capital cost of establishing 
production of a particular generic drug is high (including the cost of getting US 
Food and Drug Administration (FDA) approval), then the owner of the existing 
plant can discourage entry by dropping the price to a level that would make it 
uneconomic for a new entrant. 
 
While the patent lasts the profits for the owner of the patent are very high. (Over 
the life time of the drug, when the cost of research and development is included, 
the true economic profits will be substantially lower than the accumulated profits 
from actually manufacturing the drug – the cost of manufacture is small relative 
to the R&D costs). The practise with most of these pharmaceutical firms is that 
the drugs are sold from Ireland and the profit – the sale price less the short-run 
cost of production - arises in Ireland. However, the firms also pay very substantial 
royalties to their parent company for the right to produce the drug3. To the 
extent that such royalties are paid abroad the profits in Ireland are reduced and, 
hence, the taxes arising in Ireland are also reduced. The outflow of royalties also 
reduces the value added arising in Ireland. These royalty payments are treated as 
services imports in the national accounts and the residual profits due to the 
foreign multinational parent are treated as profit repatriations, part of net factor 
income in the national accounts. 
 
FIGURE 1 Real Output of Pharmaceuticals (NACE21), Seasonally Adjusted
 
 
Source:  Central Statistics Office, Industrial Production and Turnover Index 
                                                          
3  Of course the parent company may choose to receive the royalties in a jurisdiction other than where it has its 
headquarters or where the research was actually undertaken. 
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It has been known for some considerable time that patents on a number of very 
important and profitable drugs would run out in this decade.4 The effect of key 
patents running out is that the value of output of the firm will fall by a very 
significant amount, even if the firm continues to produce the same chemical 
compound after the patent expires. Given the importance of the pharmaceutical 
sector to Ireland, such changes may well affect macro-economic aggregates in a 
noticeable fashion. 
 
Figure 1 shows both the raw seasonally adjusted series for the volume of output 
of the Pharmaceuticals sector (NACE 21) and a 6 month moving average of that 
series. As can be seen from the Figure, the monthly series shows a lot of noise 
but it is useful in identifying where significant changes in trend may have 
occurred. These data suggest significant falls in output at the end of 2011 and in 
the late summer of 2012.5 This was almost certainly primarily because a drug (or 
drugs) dropped out of patent around the time of the change in trend.  
 
The smoothed 6 month moving average series shows a very rapid rise in the 
volume of output from 2009 to 2010. However, the pattern of growth changed 
towards the end of 2011. The smoothed series falls from then until the late spring 
of 2012. There was some further growth in output until August 2012 when the 
trend changed again resulting in another step change downwards in output. This 
shows up in Figure 1 as a marked change in direction in the series for the 6 month 
moving average of output from the autumn of 2012 until the spring of 2013. The 
smoothed series reverted to growth from March 2013 through to June.  
 
The pattern of change shown by the series suggests two discrete changes, 
probably due to patent status changes, leading to once off declines in the value of 
sales and, hence, of output. However, these discrete downward adjustments in 
sales in those months are superimposed on a tendency for output elsewhere in 
the sector to rise in the absence of the expiry of patents.  
 
While there are no published data on the actual magnitude of the effect of the 
ending of patents on the value and volume of the gross output (turnover) of the 
sector, a possible crude estimate of the magnitude of the effect can be derived 
on certain very restrictive assumptions. In June 2013 the 6 month moving average 
                                                          
4  An example of such a drug is Lipitor. The patent for Lipitor, produced by Pfizer, ran out in the US in 2011 and in 
Europe in 2012. According to Pfizer’s annual report, sales revenue from the drug worldwide fell in 2012 by $5.6 
billion. Ireland was a major site for the production of that drug. 
5  These changes roughly coincide with the expiration dates for the patent for Lipitor in the US and in Europe. However, 
quite a number of other drugs have also fallen out of patent over the last two years. 
  
of the index of the volume of gross output in the sector was down 8 per cent on 
its peak level (in 2012). If all of the fall in output were due to the loss of patents 
this would provide a crude estimate of the effect of the change. However, to the 
extent that there was a trend increase in output of drugs not covered by the 
patent status change, this number would underestimate the effects of the drugs 
dropping out of patent. On the other hand, if the EU recession was contributing 
to a fall in output, this estimate could exaggerate the effects of the patent status 
changes. On balance, because of the apparent underlying growth in the series 
discussed above, this estimate of the effect on the volume of output is likely to be 
conservative. In any event, this number should be considered as being purely 
illustrative in nature. 
 
Figure 2 shows the path of employment in the broad sector of chemicals and 
pharmaceuticals (NACE sectors 20 and 21). While there was a substantial drop in 
the period to 2010, employment flattened out thereafter. However, there was 
some further fall in employment in the last two quarters of 2012 coinciding with 
the likely ending of patents, suggesting a real fall in output however it is 
measured. As discussed later, this fall in output, because it affected employment, 
would have also affected the volume of value added in the sector. However, 
compared to the changes in value arising from the loss of profits / royalties, the 
effect of the change in the wage bill on the volume of value added (and hence of 
GDP and GNP) would have been more limited. To simplify the exposition we 
concentrate first on the potential effects of the loss of patent status on profits 
and royalties and return at the end of this note to the effect on the wage bill and 
value added. 
FIGURE 2 Employment in Chemicals and Pharmaceuticals
 
 
Source:  Central Statistics Office, Census of Industrial Production 
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Taking the Census of Industrial Production figure for the turnover of the sector in 
2010, projecting it forward to 2011 using the turnover index, this would suggest 
gross output for the sector in 2011 of around €38 billion. This would mean that 
an 8 per cent fall in output would amount to around a €3 billion loss of revenue. 
This would also amount to a fall in merchandise exports of around 3.5 per cent. 
 
One would normally expect that the direct effect of the changes in the 
profitability of foreign owned drug companies on Irish national income would be 
quite limited. The multinational owner of the plant would receive lower profits 
corresponding to lower sales revenue and one would expect that the net effect 
on the volume of Irish output would be zero. However, because of national 
accounting conventions, it actually has an appreciable effect on a number of the 
components of national income, while probably leaving real GNP largely 
unchanged. 
 
The first item that it affects is the volume of gross output in the industrial sector, 
as measured by the output volume index. This is due to the way changes in 
patent status are treated in calculating the volume index. For national accounting 
purposes the drug covered by the patent is treated as a different product from 
the equivalent generic drug, which in all other respects is similar to the patented 
drug. Thus, when a drug falls out of patent but the firm continues to produce the 
same chemical compound without patent protection, it is treated as a different 
product. At the same time, as a result of the change in patent status, there is a 
dramatic fall in revenue from selling the drug in the month when the patent ends.  
 
To calculate the volume of output the CSO takes the value of sales and deflates it 
by a suitable price index. This price index includes only drugs which were on sale 
both in the last month when the patent applied and in the first month when the 
patent had ended. Because the ending of the patent is treated as giving rise to a 
new drug, this drug (whether patented or generic) is excluded from the price 
index. Thus the price index does not change between the two months, while the 
value of sales of the specific drug, which loses its patent protection, falls 
dramatically. As a result, all of the fall in the value of sales due to the loss of 
patent protection is treated as a fall in the volume of production. While this maye 
seem counterintuitive it is the standard national accounting practise. 
 
The ultimate effects of this national accounting treatment on the key national 
accounts aggregates depends crucially on whether the fall in the company’s 
revenue  results in a fall in royalty payments or a fall in the profitability in the 
company in Ireland. While, in practise, some companies may not pay royalties 
  
and earn profits in Ireland, it is simpler to consider the two approaches 
separately. Set out below are illustrative examples of how these two eventualities 
are treated in the national accounts. In each case the numbers used are purely 
illustrative. 
 
Changes in Royalty Payments 
Table 1 uses these illustrative numbers to show how a fall in revenue of €3 billion 
would be treated in the national accounts in the case where all of the loss of 
revenue results in a fall in imports of royalties (payments abroad of royalties). In 
this case the value of gross output would fall by the €3 billion as would the value 
of exports. However, the firm would no longer pay royalties or licenses to the 
parent firm for the patent. The result would be a fall in imports of royalties of €3 
billion and a corresponding fall in inputs (of royalties) used by the firm. The net 
result of these transactions would be to leave GVA in the sector unchanged and 
also to leave GDP and GNP unchanged. 
 
TABLE 1 Illustrative National Accounts Treatment of ending of patent:  
 Fall in Import of Royalties, €millions, current prices 
 
Output Expenditure 
   Before After Change   Before After Change 
Gross output 38,000 35,000 -3,000 Exports 36,000 33,000 -3,000 
Royalties (services imports)     -3,000 Imports 22,000 19,000 -3,000 
GVA 14,000 14,000 0         
Wages 1,300 1,300 0         
Profits 12,700 12,700 0         
Corporation tax 1,588 1,588 0         
Profits after tax 11,113 11,113 0         
GDP 14,000 14,000 0 GDP 14,000 14,000 0 
Factor Income 0 0   Factor Income 0 0   
GNP 14,000 14,000 0 GNP 14,000 14,000 0 
 
In real terms there would be a corresponding fall in the volume of gross output 
and of exports. This would be exactly matched by a fall in the volume of imports 
of royalties. This would mean that the deflator for exports would change 
consistent with the change in the deflator for output. Similarly the deflator for 
services imports of royalties, whether used as an import or classified as an input, 
would change to ensure that the volume change in imports (in € billion) was 
identical to the volume change in exports. This would mean that, to ensure 
consistency, the volume of GVA in the sector would be derived using what is 
referred to as the double deflation method, rather than by applying the same 
deflator that is used for gross output. This means that the deflator applied to the 
inputs (of royalties) would be different from the implied deflator for value added. 
  
The result would be that all of the fall in the volume of gross output would be 
reflected in the fall in the volume of imported inputs, with the result that there 
would be no change in the volume of GVA (or in its deflator). 
 
This treatment would mean that there would be large visible changes in the 
national accounts and other published data for gross output and also for exports 
and imports, but there would be no effect on GDP or GNP. This seems sensible 
where the volume of the physical output of the pharmaceutical sector was 
unchanged and the only change was in the profitability of the parent firm. 
 
Changes in Profits 
An alternative possible treatment would be that the firms involved take the 
effects of the loss of patent as a reduction in their profits earned in Ireland. This is 
illustrated in Table 2. In this case the value of gross output and exports would 
also fall by €3 billion. However, in this case the loss of revenue would not result in 
a fall in royalties paid as imports of services (or a fall in inputs). Instead the value 
of GVA arising in the sector would also fall by €3 billion. In turn, with the wage bill 
unchanged, the reduction in profits would also amount to €3 billion. To the 
extent that these profits were taxable in Ireland the fall in profits would result in 
a fall in domestic corporation tax revenue. Here it is assumed for illustrative 
purposes that all of the reduction in profits was taxable at the 12.5 per cent rate 
so that tax revenue would fall by €0.375 billion. 
 
TABLE 2 Illustrative National Accounts Treatment of ending of patent: 
 Fall in Irish Profits, €millions, current prices 
 
Output       Expenditure       
  Before After Change   Before After Change 
Gross output 38,000 35,000 -3,000 Exports 36,000 33,000 -3,000 
Royalties (services imports)     0 Imports 22,000 22,000 0 
GVA (Gross Value Added) 14,000 11,000 -3,000         
Wages 1,300 1,300 0         
Profits 12,700 9,700 -3,000         
Corporation tax 1,588 1,213 -375         
Profits after tax 11,113 8,488 -2,625         
GDP 14,000 11,000 -3,000 GDP 14,000 11,000 -3,000 
Factor Income 0 0 -2,625 Factor Income   -2,625 -2,625 
GNP 14,000 13,625 -375 GNP 14,000 13,625 -375 
 
As discussed above, the reduction in GDP (GVA arising in the sector) would be €3 
billion. However, unlike the earlier case, the profits accruing to the foreign owner 
of the firms (Factor Income paid abroad) would only fall by €2.625 billion, 
reflecting the fact that domestic taxes would also fall (in this illustrative case by 
  
€0.375 billion). The net effect would be a substantial fall in GDP but only a small 
fall in GNP, equivalent to the loss of tax revenue.  In volume terms the effects 
would be similar to the value effects shown above, assuming that the price 
deflators for all relevant items handle the ending of the patent in a consistent 
manner.   
 
Possible Impact on National Accounts 
These two examples show that, depending on which of these accounting models 
is adopted by the firms experiencing a loss of patents, it can make a big 
difference to the national accounts. Where the impact of the ending of patents is 
chiefly on royalty payments, there would be no effect on GDP but substantial 
effects on exports and imports; in the case where all the effect is on profits, there 
would be a similar large impact on exports but also, in this case, on the trade 
balance and on GDP in both value and volume. In the case where profits fall there 
could also be a small impact on GNP and the current account of the balance of 
payments (equivalent to the lost tax revenue).  
 
Table 3 provides an estimate of the possible impact on key national accounts 
aggregates under the two different accounting treatments. As discussed above, in 
each case the fall in gross output as a result of the ending of the patents is 
assumed to be around 8% of the 2011 level of gross output. (As indicated earlier, 
this number is very crude and is used for illustrative purposes.) It is also likely that 
the effects of the changes would have been spread over 2012 and 2013. Hence 
the estimates shown in Table 3 are for the cumulative impact of the loss of 
patents. 
 
TABLE 3 Possible Cumulative Impact on Key Economic Aggregates using Illustrative Numbers 
  
Accounting Treatment 
  
Royalties Irish Profits 
 
€ billion % % 
Merchandise exports 85.9 -3.5 -3.5 
Exports 165.8 -1.8 -1.8 
Imports 127.9 -2.4 0.0 
GVA manufacturing 31.5 0.0 -9.7 
GDP 158.7 0.0 -1.9 
GNP 127.0 0.0 -0.3 
 
Whichever treatment is used, the impact on merchandise exports would have 
been to reduce them in both volume and value by around 3.5 per cent. In the first 
six months of 2013 the volume index for merchandise exports has been 
substantially lower than in 2012.  
  
The effect on imports depends on the way the companies treat the effects of the 
fall in revenue. In the case where royalty payments fall, the reduction in the value 
and volume of imports, while of the same absolute magnitude as the change in 
exports, would have been around 2.4 per cent. However, if all of the impact was 
on domestic profits then the impact on imports would have been zero.  
 
In the case where companies just reduce their payment of royalties there would 
be no other effects on GVA, GDP or GNP. However, in the case where all of the 
fall in revenue shows up as a fall in profits in Ireland, the negative impact on GVA 
in manufacturing would be very large at around 9.7 per cent. This would result in 
a reduction in GDP of 1.9 per cent. While there would have been no impact on 
GNP in the case of a reduction in royalty payments there could be a small impact 
(-0.3 per cent) in this case as a result of a possible loss of tax revenue. 
 
Whichever treatment is used by firms when accounting for the loss of patent 
income, the effects on real GNP are likely to be small. This correctly reflects the 
fact that nearly all of the direct cost of the loss of patent protection accrues to 
the foreign owners of the plants located in Ireland. This emphasises the 
importance of concentrating on the trend of GNP rather than the trend of GDP 
when trying to understand underlying developments in the Irish economy.6 
 
To the extent that the loss of revenue from the ending of the patents is treated as 
a reduction in imports of royalties, as indicated above, it would mean that both 
GDP and GNP (value or volume) would be largely unaffected by the change in 
patents unless the plant closes. Instead, in the national accounts figures for 2012 
and 2013 the main effect would be to reduce exports and imports by a similar 
absolute amount in value and volume. However, as discussed in this Quarterly 
Economic Commentary, the published Quarterly National Accounts for the first 
two quarters of 2013 are best reconciled with other labour market data for the 
same period if the ending of the patents has resulted in a substantial reduction in 
the profits of the companies recorded in Ireland rather than through a reduction 
in royalties. 
 
Possible Permanent Impact on GNP 
The longer term economic impact of the ending of the patents may be more 
substantial than the short-term impact. As shown here, whichever treatment is 
used the impact of a loss of sales revenue for a foreign firm should wash out of 
                                                          
6  However, account must be taken of the effect of the earnings of redomiciled PLCs. as discussed in the Spring 2012 
QEC. 
  
the national accounts, leaving Irish GNP largely unchanged. However, if 
employment is lost because a plant shuts down or if tax revenue falls there would 
be a real impact on GNP. 
 
 While the need to undertake major investment in physical plant and in obtaining 
permits in order to produce generic equivalents of what are very sophisticated 
drugs provides a substantial barrier to entry, in the longer term production of 
these generic drugs could move from Ireland to lower cost locations. In particular, 
if a company has suitable plants elsewhere where costs are lower, the production 
could be relocated by the company.  
 
Already there have been announcements of closures and job losses in Ireland as a 
result of patents ending.7 These closures involve the movement of the 
manufacture of the out of patent drugs to locations outside Ireland. In this case 
there is a real impact on GNP and GDP amounting to the loss of the wage bill and 
any taxes paid in Ireland by the companies concerned. If the fall in employment in 
the last two quarters of 2012 is indicative of a movement of production of 
generics to other countries, this would have an impact on GVA in the 
pharmaceuticals sector and on GDP and GNP. However, the magnitude of the 
impact on aggregates such as exports would be much smaller than in the case of 
the reduction in profits because of the ending of the patent. This is because the 
wage bill in the sector is less than 5 per cent of the gross output of the sector in 
Ireland. 
                                                          
7  Pfizer have already announced the closure of a plant in Ireland and resulting job losses as a consequence of the loss 
of the Lipitor patent. 
